Our Commitment to Combating Ebola

We have an important responsibility as a leading global healthcare company to do all we can to address this urgent unmet medical need.

Alex Gorsky, Chairman and CEO
Johnson & Johnson

Janssen’s Ebola Vaccine

The preventive Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), contains vaccines based on:

- Janssen’s AdVac® technology (Zabdeno®)
- Bavarian Nordic’s MVA-BN® technology (Mvabea®)

Available clinical data indicate that the two-dose regimen induces a robust and durable immune response.¹ ²

Our Progress

225,000+ people worldwide vaccinated with at least the first dose

15 Janssen clinical studies

Phase 1, 2, 3 trials show robust and durable antibody response

European Commission Approval & WHO Prequalification for Janssen’s preventive Ebola vaccine

Studies Spanning 3 Continents

*indicates studies for which Janssen were collaborators.
Ebola Timeline

The Ebola virus was first discovered in 1976 near the Ebola River in what is now the Democratic Republic of the Congo (DRC). Over the past 45 years, there have been multiple Ebola outbreaks. The worst to date was the West African Ebola epidemic, which caused nearly 30,000 cases and more than 11,000 deaths across Guinea, Liberia, and Sierra Leone in 2014-2016. The world’s second-largest Ebola outbreak took place in the DRC in 2018-2020, causing more than 3,000 cases and 2,000 deaths. In 2021, new outbreaks were reported in the DRC and Guinea.

2002
Janssen begins vaccine research with NIH support against filoviruses, which include Ebola virus.

2014
Public Health Emergency of International Concern was declared by WHO for the Ebola outbreak in West Africa.
J&J commits to accelerate development and expand production of an Ebola vaccine regimen together with Bavarian Nordic.

First clinical data for Ebola vaccine regimen published in JAMA.
Janssen completes submission to WHO for Emergency Use Assessment and Listing (EUAL).

2015
First clinical data for Ebola vaccine regimen published in JAMA.

2016
Announcement of IMI-supported consortia, including financial support from the Biomedical Advanced Research and Development Authority (BARDA).
New partnership with BARDA to support U.S. licensure of vaccine regimens.

2017
Second-largest Ebola outbreak begins in North Kivu, DRC.
The European Commission approves Janssen’s Ebola vaccine regimen.

2019
WHO prequalifies Janssen’s Ebola vaccine regimen.
J&J announces it will provide up to 200,000 vaccine regimens to a WHO early access clinical program in West Africa.
To date, more than 225,000 people worldwide have been vaccinated with at least the first dose of Janssen’s Ebola vaccine regimen.

Commitment to Pandemic Preparedness

Johnson & Johnson is one of the few innovative healthcare companies that is actively engaged on pandemic preparedness and response. Through our Janssen Pharmaceutical Companies, we are developing new vaccines and/or treatments to combat infectious diseases, including:

• COVID-19
• Ebola
• Hepatitis B
• HIV
• Influenza
• Tuberculosis
• Zika

To this end, we are partnering with leading scientific institutions, governmental agencies, and the global health community to advance R&D and manufacturing capabilities, develop new public health tools and assets, and ensure access to life-saving medicines.

Working in Partnership

Johnson & Johnson has made a significant investment in our Ebola vaccine development program. We are also grateful for development and funding support from:

• Bavarian Nordic A/S
• Biomedical Advanced Research and Development Authority (BARDA)
• Innovative Medicines Initiative (IMI)
• National Institutes of Health (NIH)

Additionally, we acknowledge the support of our many clinical program partners:

• Centre Muraz
• Coalition for Epidemic Preparedness Innovations
• College of Medicine and Allied Health Sciences (University of Sierra Leone)
• Democratic Republic of the Congo Ministry of Public Health
• Grameen Foundation
• Inserm
• Inserm Transfert
• London School of Hygiene & Tropical Medicine
• Ministry of Health and Sanitation Sierra Leone
• Republic of Rwanda Ministry of Health
• Uganda Virus Research Institute
• University of Antwerp
• University of Oxford
• Université de Kinshasa
• Vibalogics GmbH
• Walter Reed Army Institute of Research
• World Health Organization
• World Vision Ireland
• Welcome Trust

...and all the people who participated in clinical trials during the Ebola epidemic.

References


Program Support and Funding

Janssen’s investigational Ebola vaccine regimen was developed in collaboration with the NIH and received direct funding and practical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, under Contract Numbers HHSN268201400073C and HHSN268201500004C, respectively. Further funding for the Ebola vaccine regimen has been provided in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, BARDA, under Contract Numbers HHSN268201300002C and HHSN268201500008C. The Innovative Medicines Initiative (IMI), which is supported by the European Commission, provided funding through the IMI 2 program to support a number of Janssen’s and other companies’ Ebola vaccine regimens, including adenovirus type 26 (Ad26.ZEBOV) and modified vaccinia Ankara (MVA-BN-Filo) vaccines used in the Janssen regimen. A study of the Janssen vaccine regimen in the DRC was supported through the Innovative Medicines Initiative Joint Undertaking (JU) under grant agreement No 115341 and No 115421. This JU is co-funded by the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).